Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT
26.6.2020 16:50:00 EEST | Business Wire | Press release
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Application (MAA) for pexidartinib for the treatment of a subset of adult patients with severe tenosynovial giant cell tumor (TGCT). The European marketing authorization application was based on results of the pivotal phase 3 ENLIVEN study, which were published in The Lancet on June 19, 2019.1
“We will evaluate feedback received from the Committee in order to determine the appropriate next steps for pexidartinib in the EU. Despite this setback, we continue to believe in the potential of pexidartinib for people with TGCT, who often face debilitating symptoms and currently have no approved systemic treatment option,” said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo.
About Pexidartinib
Pexidartinib is an oral small molecule that inhibits CSF1R (colony stimulating factor-1 receptor), which is a primary growth driver of abnormal cells in the synovium that cause TGCT. Pexidartinib also inhibits KIT and FLT3-ITD. Pexidartinib was discovered by Plexxikon Inc., the small molecule structure-guided R&D center of Daiichi Sankyo.
About TGCT (PVNS/GCT-TS)
TGCT, also referred to as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is a rare, typically non-malignant tumor that can be locally aggressive. TGCT affects the synovium-lined joints, bursae and tendon sheaths, resulting in reduced mobility in the affected joint or limb.2,3,4 Given TGCT is rare, it’s not known exactly how many people are diagnosed with the condition each year.
The current standard of care for TGCT is surgical resection.2,5 However, in patients with a recurrent, difficult-to-treat, or diffuse form of TGCT, the tumor may wrap around bone, tendons, ligaments and other parts of the joint. In these cases, the tumor may be difficult to remove and/or may not be amenable to improvement with surgery. Multiple surgeries for more severe cases can lead to significant joint damage, debilitating functional impairments and reduced quality of life, and amputation may be considered.5,6,7
Recurrence rates for localized TGCT are estimated to be up to 15 percent following complete resection.8,9 Diffuse TGCT recurrence rates are estimated to be about 20 percent to 50 percent following complete resection.4,9,10 TGCT affects all age groups; the diffuse type on average occurs most often in people below the age of 40, and the localized type typically occurs in people between 30 and 50 years old. 2
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
References
1 Tap W D, et al. The Lancet. 2019; 394(10197);478-487.
2 de Saint Aubain, et al. WHO. 2013;100-103.
3 Rao AS, et al. J Bone Joint Surg AM. 1984;66(1):76-94.
4 Ravi V, et al. Curr Opin Oncol. 2011;23:361-366.
5 Verspoor FGM, et al. Rheumatol. 2014;53(11):2063-2070.
6 Verspoor FGM, et al. Future Oncol. 2013;10:1515-1531.
7 Brahmi M, et al. Curr Treat Options Oncol. 2016;17(2):10.
8 Gouin F, Noailles T. Orthop Traumatol Surg Res. 2017;103(1S):S91-S97.
9 Palmerini E, Staals EL, Maki RG, et al. Eur J Cancer. 2015;51(2):210-217.
10 Xie GP, et al. PLOS One. 2015;10(3):e0121451.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005278/en/
Contact information
Media Contacts:
EU
Lydia Worms
Daiichi Sankyo Europe
Lydia.Worms@daiichi-sankyo.eu
+49 89 7808751 (office)
+49-176-11780861 (mobile)
Japan
Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
+81 3 6225 1126 (office)
U.S.
Kimberly Wix
Daiichi Sankyo, Inc.
kwix@dsi.com
+1 908 992 6633 (office)
+1 908 656 5447 (mobile)
Investor Relations Contact:
DaiichiSankyoIR@daiichisankyo.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 18:00:00 EET | Press release
Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 16:30:00 EET | Press release
Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release
Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release
Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release
NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
